Failed dissolution specifications
All Recalls
95,123 total recalls in our database
Failed Stability Specification; out of specification (OOS) results for a preservative at 9 month stability study.
Superpotent Drug: product may contain concentrations of oxytocin higher than what is represented on the label.
Divalproex Sodium Extended-release Tablets, USP 250 mg, 100-count bottle, Rx only, Mfd.By: Dr. Reddy's Laboratories Limited Bachupally - 500 090 India NDC 55111-533-01
Dr. Reddy's Laboratories
Failed Dissolution Specifications: Out of specification results observed for high dissolution.
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.
Superpotent Drug: product may contain concentrations of oxytocin higher than what is represented on the label.
Superpotent Drug: product may contain concentrations of oxytocin higher than what is represented on the label.
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.
Failed Impurities/Degradation Specifications: High out of specification results obtained during routine stability testing
Labeling: Incorrect expiration date.
Microbial Contamination of Non-Sterile Products: Consumer complaint and subsequent testing found lot to be out of specification for mold.
CGMP Deviations: Finished product made with lovastatin drug substance that was out of specification for individual impurity results.
Failed Stability Specification: out of specification results for Sodium Perborate
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.
Mometasone Furoate Cream, 0.1%, 45 g tube, Rx Only, Manufactured by: G&W Laboratories, Inc. South Plainfield, NJ 07080, NDC 0713-0726-37
ACP Nimble Buyer
Labeling: Not Elsewhere Classified. Mometasone Furoate Cream has an NDC typographical error.
Lack of assurance of sterility.
CGMP Deviations
Randox CALCIUM (Ca) Colorimetric Method RX Series Cat. No. CA 3871, R1. Arsenazo Reagent 9 x 51ml GTIN: 05055273200904
Randox Laboratories
Update to the carryover avoidance technical bulletin to introduce additional steps for reagent carryover avoidance with the Calcium assay on RX instruments. Carryover to the Calcium reagent results may result in falsely elevated or decreased results to both patient and QC samples.